Poolbeg Pharma (LON:POLB) Earns House Stock Rating from Shore Capital

Poolbeg Pharma (LON:POLB)‘s stock had its “house stock” rating reissued by analysts at Shore Capital in a research report issued on Friday,London Stock Exchange reports.

Poolbeg Pharma Stock Performance

Shares of LON:POLB opened at GBX 3.80 on Friday. The stock has a market capitalization of £26.48 million, a price-to-earnings ratio of -327.41 and a beta of 2.11. Poolbeg Pharma has a 1-year low of GBX 2.25 and a 1-year high of GBX 9.68. The company has a 50 day moving average price of GBX 3.31 and a 200 day moving average price of GBX 3.09.

Poolbeg Pharma Company Profile

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS).